Dr. KinyasHair Clinic · IstanbulLibrary ←
Science and Research Centre / Donor Biology and Planning

Dr. Kinyas Hair Clinic · Science and Research Centre

DUPA: Why Might the Donor Be Unreliable in Diffuse Thinning?

Thinning at the back and sides as well as on top may change the transplant decision. DUPA describes this type of diffuse miniaturisation pattern. However, not all diffuse shedding is DUPA, and one photograph cannot establish the diagnosis.

The clinical question behind the definition

Transplantation aims to select follicles from a region that is reliable in the long term. With diffuse involvement, the question is not only how to cover the bald area, but whether a genuinely preserved donor exists. [1], [2]

A higher hair count must not take priority over this biological question. If a reliable donor cannot be identified, standard scalp transplantation may be inappropriate. The decision rests on diagnosis and individual donor assessment rather than the size of the thinning area. [1], [2]

How does the 2026 review describe uncertainty?

Spindler and colleagues emphasise the lack of established histopathological criteria and standard trichometric thresholds for DUPA. Their article is a literature and expert review, not a new clinical trial. Diagnosis combines history, examination, trichoscopy and, where indicated, biopsy. [3]

A single miniaturisation percentage found online should therefore not become a definitive diagnosis or surgical rule for everyone. Progression and alternative causes of shedding need assessment. [1], [2]

Telogen shedding and other similar presentations

Sudden or prolonged diffuse shedding can have different causes. Telogen effluvium and diffuse alopecia areata are important differential diagnoses. The appearance of thinning alone does not explain its cause. [3]

Medical and medication history, onset, regional comparisons and skin findings are assessed together. Tests are selected for the clinical question. Neither stopping a suspected medication yourself nor starting a ready-made injection package before diagnosis is justified by these observations. [1], [2] (clinical assessment recommendation)

Why a two-patient report has limited scope

In 2026, Xu and colleagues assessed the vertex and occiput in two men using trichoscopy and biopsy. Miniaturisation was reported in both regions, with partial improvement over six months of medical follow-up. This uncontrolled report proves neither general treatment efficacy nor the safety of subsequent surgery. [4]

The report’s value is in showing why presumed occipital preservation should be questioned through assessment. Its biopsy protocol does not mean the same procedure is mandatory for everyone. Clinical justification and diagnostic uncertainty matter. [1], [2]

Why monitoring is part of a treatment plan

When the nature of the loss and donor reliability are uncertain, diagnosis and monitoring may come first. The purpose is to understand risk before a surgical decision that has limited reversibility. Treatment selection requires its own benefit–risk assessment. [1], [2]

Improved appearance during one period does not establish that the donor is now safe under all circumstances. Durability of improvement and disease progression require follow-up. This text proposes no standard drug dose, mandatory schedule or guaranteed recovery time for DUPA.

What to discuss explicitly at consultation

If you have been told you have DUPA, ask which findings support it, how alternatives were assessed and how it changes the surgical target. Diagnostic uncertainty should be visible in the written plan. [1], [2] (patient communication recommendation)

This article does not claim that Dr. Kinyas’s clinic has a specific DUPA success series. Patient information should explain that recommending against unsuitable surgery can also be part of an individual plan. Promising more grafts cannot replace diagnostic clarity.

References and access limitations

This article is based on a targeted review of sources; it is not an original systematic review.

  1. ISHRS FUE Advancement Committee. FUE Clinical Practice Guidelines. 15 July 2019.

    Professional expert guidance. It does not replace individual examination or establish a fixed safe percentage or total count.

  2. Mysore V et al. Hair Transplant Practice Guidelines. J Cutan Aesthet Surg. 2021;14:265–284. DOI: 10.4103/JCAS.JCAS_104_20.

    Expert practice guidance. Includes expert opinion where evidence is lacking; not presented as Turkish legislation or a universal standard of care.

  3. Spindler A et al. Revisiting Diffuse Unpatterned Alopecia: Reappraisal of a Controversial Diagnosis. Skin Appendage Disord. 27 June 2026 online. DOI: 10.1159/000553269. PMID: 42583616.

    2026 literature and expert review. Publisher abstract, clinical assessment, diagnosis and declarations sections were accessed. Standard DUPA thresholds and histopathological criteria are not established. No funding; some authors disclose industry consulting/research and editorial relationships. Coauthor Jerry Shapiro is not the author of Ronald Shapiro’s textbook.

  4. Xu Y et al. Case Report: Paired vertex-occipital assessment reveals donor-area involvement in diffuse unpatterned alopecia. Front Med. 30 March 2026. DOI: 10.3389/fmed.2026.1797275. PMID: 41982548.

    Two-patient case report. The primary article’s abstract and clinical data/methods/table were accessed. Paired vertex/occipital trichoscopy and biopsy in two men; six-month medical follow-up. No control group; does not establish surgical safety or generalisable treatment efficacy. Full conflicts-of-interest review was not performed.

← Back to section
WhatsApp
DR. KINYAS HAIR CLINIC

Quick Contact

Leave your details and we will contact you through your preferred channel.

How should we contact you?

Dr. Kinyas Hair Clinic uses your details to respond to your request and contact you.